Literature DB >> 10584216

A model for the binding of low molecular weight inhibitors to the active site of thrombin.

M C Allen1, X L Cockcroft, M G Gruetter, J P Priestle.   

Abstract

This paper describes the construction, validation and application of an active site model of the serine protease thrombin. Initial use was made of medium resolution X-ray crystallographic structures of thrombin complexed with low molecular weight, non-specific inhibitors to create a computationally useable active site shell of the enzyme. Molecular mechanics methods were then applied to dock known ligands into the active site region in order to derive a model that would accurately predict binding conformations. Validation of the modelling process was achieved by comparison of the predicted enzyme-bound conformations with their known, crystallographic binding conformations. The resultant model was used extensively for predictive purposes prior to obtaining confirmatory crystal data relating to a ligand possessing a novel and unexpected binding component complexed to thrombin. The data served both to confirm the accuracy of the binding site model and to provide information for the further refinement of the model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584216     DOI: 10.1023/a:1008098615891

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  8 in total

1.  Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors.

Authors:  D W Banner; P Hadváry
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

2.  Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.

Authors:  T J Tucker; S F Brady; W C Lumma; S D Lewis; S J Gardell; A M Naylor-Olsen; Y Yan; J T Sisko; K J Stauffer; B J Lucas; J J Lynch; J J Cook; M T Stranieri; M A Holahan; E A Lyle; E P Baskin; I W Chen; K B Dancheck; J A Krueger; C M Cooper; J P Vacca
Journal:  J Med Chem       Date:  1998-08-13       Impact factor: 7.446

Review 3.  Thrombin.

Authors:  J W Fenton
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

4.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

5.  Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.

Authors:  R M Lidón; P Théroux; M Juneau; B Adelman; J Maraganore
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

6.  Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.

Authors:  R Kikumoto; Y Tamao; T Tezuka; S Tonomura; H Hara; K Ninomiya; A Hijikata; S Okamoto
Journal:  Biochemistry       Date:  1984-01-03       Impact factor: 3.162

7.  Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.

Authors:  E J Topol; V Fuster; R A Harrington; R M Califf; N S Kleiman; D J Kereiakes; M Cohen; A Chapekis; H K Gold; M A Tannenbaum
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

8.  The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.

Authors:  W Bode; I Mayr; U Baumann; R Huber; S R Stone; J Hofsteenge
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.